Opinions
The Panic-Proof Portfolio (Stockchase Research)
Cullinan Oncology, Inc.
CGEM-Q
TOP PICK
Jun 06, 2023
$12.290
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Stockchase Research Editor: Michael O’Reilly
CGEM is a unique pharmaceutical company that collaborates with other developers and academia to develop drugs to help cancer patients. It has six on-going products in its pipeline. It trades below book value, at 6x earnings, and supports a 19% ROE. We like that it is low beta compared to the market. We recommend a stop-loss at $8.50, looking to achieve $17 — upside potential of 50%. Yield 0%
(Analysts’ price target is $28.75)
biotechnology
pharmaceutical
PAST TOP PICK
(A Top Pick Jun 06/23, Down 30.8%)Stockchase Research Editor: Michael O’Reilly
Our PAST TOP PICK with CGEM has triggered its stop at $8.50. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 27%, when combined with previous recommendations.
biotechnology
pharmaceutical
We reiterate this biopharma company focused on oncology therapies, as a TOP PICK. Pilot projects are continuing to advance and they have a growing pipeline of new prospects. It trades under book value, supporting a 14% ROE. Cash reserves are growing, while debt is retired. We recommend maintaining the stop at $8.50, looking to achieve $17.00 -- upside of 36%. Yield 0%
(Analysts’ price target is $29.00)